Panther Biotechnology Inc (PBYA) 0.2400 $PBYA
Panther Biotechnology, Inc. Announces $1.215 Million Financing With Chicago Venture Partners
Marketwired - Tue Aug 25, 5:00AM CDT
Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the acquisition and development of enhanced therapeutics for the treatment of neoplastic, autoimmune and antiviral disorders, today announced that it has executed a convertible note with a strike price of $7.50 with Chicago Venture Partners.
Panther Biotechnology Announces the Closing of the Acquisition of Technology Assets of Faulk Pharmaceuticals
Marketwired - Thu Jul 16, 7:59AM CDT
Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the acquisition and development of enhanced therapeutics for the treatment of neoplastic, autoimmune and antiviral disorders, is pleased to announce today that it has closed definitive agreements with privately held Faulk Pharmaceuticals, Inc. to acquire Faulk's pharmaceuticals technology assets. The transaction provides Panther Biotechnology with a proprietary, multinational patent protected, ligand-drug conjugate technology platform as well as a pipeline of drug product candidates that address unmet medical needs in oncology, autoimmune, antiviral and other disease indications.
Panther Biotechnology Announces the Acquisition of Alchemia Oncology Pty Limited
Marketwired - Wed Jul 01, 5:30AM CDT
Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the acquisition and development of enhanced therapeutics for the treatment of neoplastic, autoimmune and antiviral disorders, today announced that it has entered into an agreement to acquire Alchemia Oncology Pty Limited, a wholly owned subsidiary of Alchemia Limited, an Australian biotechnology company listed on the Australian Stock Exchange (ACL).
Panther Biotechnology Reports the Fiscal Year Ended May 2014 and the First Three Quarters of Fiscal Year 2015 Bringing the Company Current in Its SEC Filing Obligations
Marketwired - Mon Jun 15, 10:40AM CDT
Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the acquisition and development of enhanced therapeutics for the treatment of neoplastic, autoimmune and antiviral disorders, today reported financial results for the year ended May 31, 2014 and for the first three quarters of fiscal year 2015. The results for such periods are primarily from our wholly owned subsidiary, Pubco, which is in the business of operating as a filing agent offering both EDGAR and XBRL services for filing and uploading securities filings to the Securities and Exchange Commission.
Panther Chairman to Step Down for Health Reasons
Marketwired - Mon Jun 01, 7:01AM CDT
Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the acquisition and development of enhanced therapeutics for the treatment of neoplastic, autoimmune and antiviral disorders, today announced that Irwin "Izzy" Zalcberg has decided to retire from the Board of Directors of Panther Biotechnology to focus on his health. Evan Levine, the Company's President and Chief Executive Officer, will assume the Chairman role.
Panther Biotechnology Announces New Drug Candidate to Selectively Kill Leukemia Stem Cells
Marketwired - Fri Apr 17, 6:30AM CDT
Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the development of enhanced therapeutics for the treatment of neoplastic disorders, is pleased to announce today that it has entered into an exclusive global license agreement with the University of Rochester.
Panther Biotechnology Announces Agreement to Acquire Technology Assets of Faulk Pharmaceuticals
Marketwired - Tue Apr 07, 6:00AM CDT
Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the development of enhanced therapeutics for the treatment of neoplastic and autoimmune disorders, is pleased to announce today that it has entered into a definitive agreement with privately held Faulk Pharmaceuticals, Inc. to acquire Faulk's pharmaceutical technology assets. The transaction will provide Panther Biotechnology with a proprietary, multinationally patent protected, ligand-drug conjugate technology platform as well as a pipeline of drug product candidates that address unmet medical needs in oncology, autoimmune, antiviral and other disease indications.
Panther Biotechnology Announces Exclusive License Agreement With Northwestern University
Marketwired - Wed Apr 01, 9:02AM CDT
Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the development of enhanced therapeutics for the treatment of neoplastic and autoimmune disorders, is pleased to announce today that it has entered into an exclusive global license agreement with Northwestern University.
Panther Biotechnology Announces New Chief Executive Officer
Marketwired - Mon Mar 23, 9:52AM CDT
Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the development of enhanced therapeutics for the treatment of neoplastic and autoimmune disorders, is pleased to announce today that Evan Levine has accepted the position of Chief Executive Officer, as well as a seat on the Board of Directors.
Panther Biotechnology, Inc. Announces $1.215 Million Financing With Chicago Venture Partners
Marketwired - Tue Aug 25, 5:00AM CDT
Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the acquisition and development of enhanced therapeutics for the treatment of neoplastic, autoimmune and antiviral disorders, today announced that it has executed a convertible note with a strike price of $7.50 with Chicago Venture Partners.
Panther Biotechnology Announces the Closing of the Acquisition of Technology Assets of Faulk Pharmaceuticals
Marketwired - Thu Jul 16, 7:59AM CDT
Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the acquisition and development of enhanced therapeutics for the treatment of neoplastic, autoimmune and antiviral disorders, is pleased to announce today that it has closed definitive agreements with privately held Faulk Pharmaceuticals, Inc. to acquire Faulk's pharmaceuticals technology assets. The transaction provides Panther Biotechnology with a proprietary, multinational patent protected, ligand-drug conjugate technology platform as well as a pipeline of drug product candidates that address unmet medical needs in oncology, autoimmune, antiviral and other disease indications.
Panther Biotechnology Announces the Acquisition of Alchemia Oncology Pty Limited
Marketwired - Wed Jul 01, 5:30AM CDT
Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the acquisition and development of enhanced therapeutics for the treatment of neoplastic, autoimmune and antiviral disorders, today announced that it has entered into an agreement to acquire Alchemia Oncology Pty Limited, a wholly owned subsidiary of Alchemia Limited, an Australian biotechnology company listed on the Australian Stock Exchange (ACL).
Panther Biotechnology Reports the Fiscal Year Ended May 2014 and the First Three Quarters of Fiscal Year 2015 Bringing the Company Current in Its SEC Filing Obligations
Marketwired - Mon Jun 15, 10:40AM CDT
Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the acquisition and development of enhanced therapeutics for the treatment of neoplastic, autoimmune and antiviral disorders, today reported financial results for the year ended May 31, 2014 and for the first three quarters of fiscal year 2015. The results for such periods are primarily from our wholly owned subsidiary, Pubco, which is in the business of operating as a filing agent offering both EDGAR and XBRL services for filing and uploading securities filings to the Securities and Exchange Commission.
Panther Chairman to Step Down for Health Reasons
Marketwired - Mon Jun 01, 7:01AM CDT
Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the acquisition and development of enhanced therapeutics for the treatment of neoplastic, autoimmune and antiviral disorders, today announced that Irwin "Izzy" Zalcberg has decided to retire from the Board of Directors of Panther Biotechnology to focus on his health. Evan Levine, the Company's President and Chief Executive Officer, will assume the Chairman role.
Panther Biotechnology Announces New Drug Candidate to Selectively Kill Leukemia Stem Cells
Marketwired - Fri Apr 17, 6:30AM CDT
Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the development of enhanced therapeutics for the treatment of neoplastic disorders, is pleased to announce today that it has entered into an exclusive global license agreement with the University of Rochester.
Panther Biotechnology Announces Agreement to Acquire Technology Assets of Faulk Pharmaceuticals
Marketwired - Tue Apr 07, 6:00AM CDT
Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the development of enhanced therapeutics for the treatment of neoplastic and autoimmune disorders, is pleased to announce today that it has entered into a definitive agreement with privately held Faulk Pharmaceuticals, Inc. to acquire Faulk's pharmaceutical technology assets. The transaction will provide Panther Biotechnology with a proprietary, multinationally patent protected, ligand-drug conjugate technology platform as well as a pipeline of drug product candidates that address unmet medical needs in oncology, autoimmune, antiviral and other disease indications.
Panther Biotechnology Announces Exclusive License Agreement With Northwestern University
Marketwired - Wed Apr 01, 9:02AM CDT
Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the development of enhanced therapeutics for the treatment of neoplastic and autoimmune disorders, is pleased to announce today that it has entered into an exclusive global license agreement with Northwestern University.
Panther Biotechnology Announces New Chief Executive Officer
Marketwired - Mon Mar 23, 9:52AM CDT
Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the development of enhanced therapeutics for the treatment of neoplastic and autoimmune disorders, is pleased to announce today that Evan Levine has accepted the position of Chief Executive Officer, as well as a seat on the Board of Directors.
